Healthcare / Medical DevicesTel Aviv
$683.30
-13.20 (-1.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-12.0M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$206M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-33.2%
↓Gross Margin
-307.0%
↓Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-4455.9%
FCF / Net income
1.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $213000.0 · net income $-8.6M · FCF $-9.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $213000.00 | $213000.00 | — | $10.0M | — |
| Net Income | $-8.6M | $-8.6M | $-1.5M | $-5.7M | $-15.4M |
| EBITDA | $-6.7M | $-6.7M | $-826000.00 | $-5.0M | $-15.0M |
| EPS | — | — | -0.05 | -0.19 | -0.52 |
| Gross Margin | -307.0% | -307.0% | — | — | — |
| Operating Margin | -4475.1% | -4475.1% | — | 4.2% | — |
| Net Margin | -4043.2% | -4043.2% | — | -56.8% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.13 | 0.11 | 0.10 |
| Current Ratio | 6.23 | 6.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.5M | $-9.5M | $-12.9M | $-12.0M | $-13.1M |
| Returns | |||||
| ROE | -33.2% | -33.2% | -4.3% | -16.3% | -39.0% |
| Valuation | |||||
| P/B | 791.53 | 791.53 | 812.48 | 329.01 | 854.34 |
| Growth & Yield | |||||
| EPS Growth | — | — | 74.5% | 63.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.05 → n/d
Residual
-23.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.